



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
ANDREA G. REISTER

WILLIAM C. ALLISON V
MICHAEL O. LEE
G. KEVIN TOWNSEND*
JOHN M. COVERT*
ANNE BROWN
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER
LORI L. KERBER*
JUDITH U. KIM*

KEITH KIND*
TIMOTHY J. SHEA, JR.*
DONALD R. MCPHAIL
PATRICK E. GARRETT*
JEFFREY W. RENNECKER
BARBARA A. PARVIS
MICHAEL A. RAHMAN*
STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*
RICK A. TOERING*
JEFFREY T. HELVEY*

18127#2
Q.E.
10/21/97

DONALD J. FEATHERSTONE**
LAWRENCE B. BUGAISKY**
KAREN R. MARKOWICZ**
KIMBERLIN M. TOOHEY**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:

October 6, 1997

INTERNET ADDRESS:

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
OCT 14 1997
GROUP 1800

Re: U.S. Non-Provisional Utility Patent Application
Appl. No. 08/874,460; Filed: June 16, 1997
For: **Chemokine β -15**
Inventor(s): **WEI *et al.***
Our Ref: 1488.0420001/EKS/KMT

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 (10 pages);
3. 42 references (AA1-AE1; AL1-AT1; AL2-A02; AR2 - AT2; AR3 - AT3; AR4 - AT4; AR5 - AT5; AR6 - AT6; AR7 - AT7; AR8 - AT8; AR9 - AT9; AR 10); and
4. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents


October 6, 1997

Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Kimberlin M. Toohey

Agent for Applicants

Registration No. 35,391

Enclosures

KMT/sal

PAUSERS\KTOOHEY\1488\042-1\IDS.TRN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

WEI *et al.*

Appl. No. 08/874,460

Filed: June 16, 1997

For: Chemokine β -15



Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 1488.0420001/EKS/KMT

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not


exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

This Information Disclosure Statement is being submitted before a first Office Action on the merits. It is therefore believed that no fees are due for consideration of this Information Disclosure Statement. Any fees which may be due may be debited to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Kimberlin M. Toohey
Agent for Applicants
Registration No. 35,391

Date: Oct 6, 1997

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600